Hemab Therapeutics (NASDAQ:COAG) Shares Gap Down – Time to Sell?

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) shares gapped down prior to trading on Wednesday . The stock had previously closed at $25.44, but opened at $24.21. Hemab Therapeutics shares last traded at $25.03, with a volume of 50,300 shares traded.

Analyst Ratings Changes

Separately, Wall Street Zen upgraded Hemab Therapeutics to a “hold” rating in a report on Saturday, May 9th.

Hemab Therapeutics Stock Up 2.4%

Insider Transactions at Hemab Therapeutics

In related news, major shareholder Ra Capital Management, L.P. bought 6,387 shares of Hemab Therapeutics stock in a transaction that occurred on Tuesday, May 12th. The shares were purchased at an average price of $24.90 per share, with a total value of $159,036.30. Following the purchase, the insider owned 6,372,170 shares in the company, valued at $158,667,033. This represents a 0.10% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Over the last 90 days, insiders purchased 2,898,074 shares of company stock valued at $53,650,008.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.